Checking Vaccine Immune Responses After CAR-T Therapy in Myeloma and Lymphoma
Observes whether vaccine protection is reduced in adults with myeloma or lymphoma after CAR-T.
Plain-language title generated from the registry record
Registry title: Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment
Key facts
- Where
- Portland, United StatesSee the site
Where in United States
- OHSU Knight Cancer InstitutePortland, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- OHSU Knight Cancer Institute
- Trial code
- NCT06784167
- Record updated
- 23 September 2026
- Original description
This study evaluates immune responses after CAR-T therapy to find out if CAR-T therapy reduces the effectiveness of the vaccines (vaccine immunity) against diseases such as measles, mumps and rubella, among others in patients with multiple myeloma and non-Hodgkin lymphoma.Read full original descriptionShow less
Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkins Lymphoma Post CAR-T Treatment
This study evaluates immune responses after CAR-T therapy to find out if CAR-T therapy reduces the effectiveness of the vaccines (vaccine immunity) against diseases such as measles, mumps and rubella, among others in patients with multiple myeloma and non-Hodgkin lymphoma.
Inclusion: * Willingness to provide written informed consent before any study-specific procedures or activities are performed; Age ≥ 18 years of age, at the time of consent; Documented, histologically or cytologically confirmed diagnosis of multiple myeloma (MM), diffuse large B cell lymphoma (DLBCL),follicular lymphoma (FL), mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL), or small lymphocytic lymphoma (SLL), or primary mediastinal B cell lymphoma (PMBL). All number of prior lines of therapy are allowed; History of prior vaccination against common VPD; Approved by managing physician for CAR-T therapy, with preparative conditioning planned within the next 90 days; Approved by managing physician for revaccination against Streptococcus pneumoniae or tetanus.
Exclusion: * Ongoing use of immunosuppressive agents or plans for immunosuppressive therapy that would interfere with interpretation of study endpoints; Uncontrolled, intercurrent illness including, but not limited to, systemic infection, symptomatic congestive heart failure, unstable angina pectoris, or psychiatric illness/social situations that would limit compliance with study requirements or make the study procedures unadvisable.